Supplemental Table 4: Hazard ratios of incident CKD by levels of urine arsenic, with regression adjustment of creatinine for urine dilution

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Sum of inorganic and methylated, μg/L** | **Cases/**  **noncases** | **Model 1** | **Model 2** | **Model 3** | **Model 4** |
| **≤6.1** | 109/663 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | -- |
| **6.1 – 10.4** | 110/671 | 1.26 (0.96, 1.64) | 1.33 (1.02, 1.73) | 1.26 (0.97, 1.65) | -- |
| **10.4 – 18.4** | 128/656 | 1.24 (0.93, 1.65) | 1.39 (1.04, 1.85) | 1.26 (0.94, 1.68) | -- |
| **≥18.4** | 155/627 | 1.42 (1.02, 1.97) | 1.67 (1.19, 2.33) | 1.42 (1.01, 2.01) | -- |
| **p-trend** |  | 0.02 | <0.01 | 0.14 |  |
| IQR (18.8 vs 6.2) | 395/3456 | 1.17 (1.00, 1.38) | 1.27 (1.08, 1.49) | 1.16 (0.98, 1.37) | -- |
| **Inorganic arsenic, μg/L** |  |  |  |  |  |
| IQR (1.7 vs 0.4) | 395/3456 | 0.89 (0.77, 1.04) | 1.05 (0.90, 1.22) | 0.97 (0.83, 1.14) | -- |
| **MMA, μg/L** |  |  |  |  |  |
| IQR (2.6 vs 0.7) | 395/3456 | 1.03 (0.88, 1.21) | 1.15 (0.98, 1.36) | 1.13 (0.96, 1.34) | 1.47 (1.12, 1.92) |
| **DMA, μg/L** |  |  |  |  |  |
| IQR (14.2 vs 4.7) | 395/3456 | 1.23 (1.05, 1.43) | 1.29 (1.10, 1.51) | 1.17 (1.00, 1.38) | 1.39 (1.11, 1.74) |
| **Arsenobetaine, μg/L** |  |  |  |  |  |
| IQR (1.7 vs 0.5) | 395/3456 | 1.01 (0.92, 1.11) | 1.01 (0.92, 1.11) | 1.06 (0.97, 1.16) | 1.06 (0.97, 1.16) |
| Model 1 is crude |  |  |  |  |  |
| Model 2 is adjusted for age and gender, location, education, smoking status, BMI, hypertension medication, SBP, and baseline eGFR | | | | | |
| Model 3 is additionally adjusted for diabetes status and fasting glucose | | | |  |  |
| Model 4 is additionally adjusted for inorganic arsenic (arsenite, arsenate) | | | |  |  |